Henry E. Pelish

1.8k total citations
22 papers, 913 citations indexed

About

Henry E. Pelish is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Henry E. Pelish has authored 22 papers receiving a total of 913 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 12 papers in Oncology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Henry E. Pelish's work include Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (7 papers) and Cancer therapeutics and mechanisms (5 papers). Henry E. Pelish is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (7 papers) and Cancer therapeutics and mechanisms (5 papers). Henry E. Pelish collaborates with scholars based in United States, France and South Korea. Henry E. Pelish's co-authors include Tomas Kirchhausen, Eric Macia, Matthew D. Shair, Jeffrey R. Peterson, Anupong Tangpeerachaikul, Andres M. Lebensohn, Marc W. Kirschner, Mark A. Stamnes, Enrique Rodríguez-Boulan and Yan Feng and has published in prestigious journals such as Cancer Research, Methods in enzymology on CD-ROM/Methods in enzymology and Annals of Oncology.

In The Last Decade

Henry E. Pelish

20 papers receiving 903 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Henry E. Pelish United States	10	594	208	130	128	84	22	913
Tatsuya Inui Japan	15	547 0.9×	176 0.8×	139 1.1×	82 0.6×	59 0.7×	34	816
Line Groth‐Pedersen Denmark	11	716 1.2×	236 1.1×	116 0.9×	45 0.4×	68 0.8×	12	1.2k
Qingxiang Sun China	20	1.0k 1.7×	213 1.0×	159 1.2×	55 0.4×	96 1.1×	59	1.4k
Siddhartha S. Jana India	18	595 1.0×	374 1.8×	83 0.6×	77 0.6×	40 0.5×	41	1.1k
Michael P. East United States	17	783 1.3×	231 1.1×	120 0.9×	86 0.7×	48 0.6×	37	1.1k
Zhe Zhou China	12	761 1.3×	146 0.7×	125 1.0×	200 1.6×	53 0.6×	19	1.0k
Margot G. Paulick United States	12	784 1.3×	138 0.7×	122 0.9×	275 2.1×	91 1.1×	14	1.1k
Chris Molenaar Netherlands	18	832 1.4×	84 0.4×	166 1.3×	102 0.8×	59 0.7×	20	1.2k
Magdalena M. Szewczyk Canada	22	1.3k 2.1×	101 0.5×	106 0.8×	70 0.5×	70 0.8×	39	1.6k

Countries citing papers authored by Henry E. Pelish

Since Specialization

Citations

This map shows the geographic impact of Henry E. Pelish's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henry E. Pelish with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henry E. Pelish more than expected).

Fields of papers citing papers by Henry E. Pelish

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henry E. Pelish. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henry E. Pelish. The network helps show where Henry E. Pelish may publish in the future.

Co-authorship network of co-authors of Henry E. Pelish

This figure shows the co-authorship network connecting the top 25 collaborators of Henry E. Pelish. A scholar is included among the top collaborators of Henry E. Pelish based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henry E. Pelish. Henry E. Pelish is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tangpeerachaikul, Anupong, et al.. (2025). Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations. Molecular Cancer Therapeutics. 24(7). 1005–1019. 1 indexed citations

Tangpeerachaikul, Anupong & Henry E. Pelish. (2025). Abstract 1729: Mutagenesis screens support potential best-in-class profile for neladalkib (NVL-655), a brain-penetrant and TRK-sparing ALK inhibitor. Cancer Research. 85(8_Supplement_1). 1729–1729. 1 indexed citations

Tangpeerachaikul, Anupong, Franklin Gu, & Henry E. Pelish. (2024). Abstract LB182: Mutagenesis screens support potential best-in-class profile for selective, brain-penetrant, and TRK-sparing ROS1 inhibitor NVL-520. Cancer Research. 84(7_Supplement). LB182–LB182.

Sun, Yuting, Kristin L. Andrews, Anupong Tangpeerachaikul, et al.. (2024). Abstract 1979: Preclinical characterization of NVL-330, a selective and brain penetrant HER2 tyrosine kinase inhibitor with broad activity on HER2 oncogenic alterations. Cancer Research. 84(6_Supplement). 1979–1979. 2 indexed citations

Lee, Jii Bum, Mi Ra Yu, Mi Ran Yun, et al.. (2023). Abstract 4022: Preclinical intracranial activity of NVL-655 in an alectinib-resistant patient-derived model harboring EML4-ALK fusion with G1202R mutation. Cancer Research. 83(7_Supplement). 4022–4022.

Besse, Benjamin, Melissa L. Johnson, S-H.I. Ou, et al.. (2022). 78TiP Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase I/II ARROS-1 study. Annals of Oncology. 33. S68–S69. 1 indexed citations

Tangpeerachaikul, Anupong, et al.. (2022). Abstract 3336: Preclinical activity of NVL-520 in ROS1-driven cancer models with diverse fusion partners and kinase-domain mutations. Cancer Research. 82(12_Supplement). 3336–3336. 1 indexed citations

Tangpeerachaikul, Anupong, Ludovic Bigot, Luc Friboulet, & Henry E. Pelish. (2022). Abstract 3337: Preclinical activity of NVL-655 in ALK-driven cancer models beyond non-small cell lung cancer. Cancer Research. 82(12_Supplement). 3337–3337. 1 indexed citations

Tangpeerachaikul, Anupong, Amit Deshpande, Nancy E. Kohl, Joshua C. Horan, & Henry E. Pelish. (2021). Abstract P244: NVL-655 exhibits antitumor activity in lorlatinib-resistant and intracranial models of ALK-rearranged NSCLC. Molecular Cancer Therapeutics. 20(12_Supplement). P244–P244. 3 indexed citations

10.

Pelish, Henry E., Anupong Tangpeerachaikul, Nancy E. Kohl, et al.. (2021). Abstract 1465: NUV-520 (NVL-520) is a brain-penetrant and highly selective ROS1 inhibitor with antitumor activity against the G2032R solvent front mutation. Cancer Research. 81(13_Supplement). 1465–1465. 4 indexed citations

11.

Pelish, Henry E., Anupong Tangpeerachaikul, Nancy E. Kohl, et al.. (2021). Abstract 1468: NUV-655 (NVL-655) is a selective, brain-penetrant ALK inhibitor with antitumor activity against the lorlatinib-resistant G1202R/L1196M compound mutation. Cancer Research. 81(13_Supplement). 1468–1468. 22 indexed citations

12.

Niţulescu, I, Sara C. Meyer, Qiang Wen, et al.. (2017). Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation. EBioMedicine. 26. 112–125. 37 indexed citations

13.

Poss, Zachary C., Christopher C. Ebmeier, Aaron Odell, et al.. (2016). Identification of Mediator Kinase Substrates in Human Cells using Cortistatin A and Quantitative Phosphoproteomics. Cell Reports. 15(2). 436–450. 114 indexed citations

14.

Marks, Kevin M., Eun Sun Park, Alexander Arefolov, et al.. (2011). The Selectivity of Austocystin D Arises from Cell-Line-Specific Drug Activation by Cytochrome P450 Enzymes. Journal of Natural Products. 74(4). 567–573. 34 indexed citations

15.

Kirchhausen, Tomas, Eric Macia, & Henry E. Pelish. (2008). Use of Dynasore, the Small Molecule Inhibitor of Dynamin, in the Regulation of Endocytosis. Methods in enzymology on CD-ROM/Methods in enzymology. 438. 77–93. 364 indexed citations

16.

Peterson, Jeffrey R., Andres M. Lebensohn, Henry E. Pelish, & Marc W. Kirschner. (2006). Biochemical Suppression of Small-Molecule Inhibitors: A Strategy to Identify Inhibitor Targets and Signaling Pathway Components. Chemistry & Biology. 13(4). 443–452. 55 indexed citations

17.

Xu, Bo, Henry E. Pelish, Tomas Kirchhausen, & Gerald B. Hammond. (2006). Large scale synthesis of the Cdc42 inhibitor secramine A and its inhibition of cell spreading. Organic & Biomolecular Chemistry. 4(22). 4149–4149. 23 indexed citations

18.

Pelish, Henry E., et al.. (2006). The Cdc42 inhibitor secramine B prevents cAMP-induced K+ conductance in intestinal epithelial cells. Biochemical Pharmacology. 71(12). 1720–1726. 7 indexed citations

19.

Pelish, Henry E., Jeffrey R. Peterson, Susana Salvarezza, et al.. (2005). Secramine inhibits Cdc42-dependent functions in cells and Cdc42 activation in vitro. Nature Chemical Biology. 2(1). 39–46. 130 indexed citations

20.

Tallarico, John A., Henry E. Pelish, Nicholas J. Westwood, et al.. (2001). An Alkylsilyl-Tethered, High-Capacity Solid Support Amenable to Diversity-Oriented Synthesis for One-Bead, One-Stock Solution Chemical Genetics. Journal of Combinatorial Chemistry. 3(3). 312–318. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact